vinit6675's blog

Market Overview 

According to MRFR, the Global Epilepsy Market is poised to acquire USD 9.50 billion valuation by 2023, exhibiting a CAGR of 8.20% over the review period (2018-2023).

Market Dynamics  

Consumer demand is predicted to be fueled by the high sensitivity risk of geriatric epilepsy. Furthermore, brain injury that can lead to post-traumatic epilepsy (PTE) and post-traumatic seizures (PTS) can increase demand for epilepsy drugs. Primary variables such as the development of experimental medicines, the advent of new pharmaceuticals in developed nations, and the incidence of neurological illnesses such as meningitis and tumours all influence the global demand for epilepsy. An improvement in healthcare prices and an increase in disposable income are also driving this upward trend.

Emerging trends, such as companies focusing on developing novel treatments for refractory epilepsy and doctors demanding more effective pharmaceuticals, are driving up R&D spending in the industry. The market is also developing because to the increasing adoption of rational polytherapy and enhanced imaging technology for early diagnosis. Furthermore, the industry is expected to benefit from the implementation of innovative digital healthcare models such as mHealth and telemedicine.

Segment Overview 

The global market for epilepsy by disorder, diagnosis & treatment, and end-use. 

The market is divided into two types of epilepsy: drug-resistant/intractable epilepsy and others. By the end of the projection period, the drug-resistant epilepsy segment is estimated to be worth USD 2.93 billion. The introduction of rational polytherapy for treating disease with minimal side effects is projected to boost the epilepsy market's revenue.

The market for epilepsy is divided into two categories: diagnosis and therapy. Due to the availability of low-cost drugs to treat partial epileptic seizures, the treatment category is likely to drive the market at a 7.91 percent CAGR over the forecast period. Furthermore, regulatory agencies' approval of successful pharmaceuticals will aid the segment's development. The diagnostic segment, on the other hand, is predicted to mature at an 8.76 percent CAGR over the evaluation period. The use of a variety of imaging and blood tests to determine the issue early on is predicted to speed up segment growth tenfold.

The epilepsy market is divided into hospitals, clinics, diagnostic centres, ambulatory surgery centres, and others based on end-users.

Over the research period, the hospital segment is expected to lead market growth, followed by clinics. In addition, hospitals that encourage the purchase of drugs on-site are more likely to support the market.

Regional Overview

The Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa make up the epilepsy industry in the region (MEA).

In 2017, the Americas accounted for 41% of the total, followed by Europe, APAC, and MEA. Because of the availability of well-established healthcare facilities, favourable government policies aimed at boosting the healthcare sector, and the presence of major research and development programmes, North America is a leading contributor to the market.

Over the forecasted period, Europe is estimated to grow at an annual rate of 8.31%. Increased investment in epilepsy research and production, combined with a high prevalence of the disease, is predicted to drive regional demand exponentially higher.

The APAC epilepsy market is expected to reach USD 2.04 million by 2023, owing to the increasing prevalence of the ailment in the region. Over the foreseeable period, consumer demand will be boosted by India, South Korea, and China, which are developing as viable destinations for studying and producing novel items.

 

The global Hepatitis B treatment market is growing rapidly, majorly due to the increasing prevalence of this condition. At the same time, there are severalnovel treatments available in the market which are increasing the size of the market, providing quality care. The emergence of many new, effective anti-viral medications is commutatively escalating the market on the global platform, offering better outcomes, lesser side-effects, and shorter treatment times.

According to Market Research Future (MRFR), the global Hepatitis B treatment marketis expected to grow moderately by 2024. In its recently published analysis, MRFR also asserts that the market would register a CAGR of approximately 5.3% throughout the assessment period (2018 -2024). The market has been witnessing severalclinical trials for testing new treatments, interventions, and tests to prevent, detect, treat, or manage the condition.

Many on-going researchto fully understand and treat the disease are achieving significant progress, which further defines the growing landscape of the Hepatitis B treatment market. Besides, increasing population and urbanization alongside, spreading awareness about the availability of treatments are contributing to the growth of the market. The rapidly improving global economy provide impetus to the market growth, enabling access to the quality life & improved healthcare.

Hepatitis B Treatment Market - Regional Analysis

North America leads the Hepatitis B treatment market with a significant market share. Attributing to the favorable reimbursement scenario and higher expenditure on healthcare, the market is expected to grow phenomenally over the forecast period. The market is expected to perceive healthy growth. Another important driver for regional market growth is the rapid uptake of new technologies in the US. Moreover, high healthcare expenditure boosts the growth in the regional market, increasing access to the quality care and best treatments for viral infection.

The Hepatitis B treatment market in the European region takes the second lead, globally. According to the World Health Organization, hepatitis B and C affect a large number of Europeans, taking away lives of 1.5 million people each year. Rising cases of acute hepatitis B and viral infection among the population along, the presence of advanced medical facilities drive the regional market growth. The resurging economy in Europe is certainly supporting the regional market growth, increasing the per capita healthcare expenditures and access to quality healthcare.  

Asia Pacific Hepatitis B treatment market is brisk, which is growing at a phenomenal CAGR. A rapidly growing medical diagnostic sector alongside, the growing prevalence of bacterial infection and a large patient population suffering from HIV infection support regional market growth. India and China backed by the vast population, and the availability of low-cost drugs for the treatment lead the regional market.

Hepatitis B Treatment Market   - Competitive Analysis

Highly competitive, the Hepatitis B treatment market appears to be fragmented with many large and small players operating in the market. These players incorporate strategic initiatives, such as acquisitions & mergers, collaboration, expansion, and technology launch to gain a competitive advantage in the market. They also invest substantially in R&D and clinical trials to develop effective drugs.

Major Players:

Players leading the global hepatitis B treatment market include Apotex Corp., Accord Healthcare Inc., Arbutus Biopharma, Aurobindo Pharma Limited, Arrowhead Pharma, Bristol-Myers Squibb Company, GlaxoSmithKline, Gilead Sciences, Inc., Lupin Pharmaceuticals, Inc., Par Pharmaceutical, Inc., Merck & Co., Inc., Teva Pharmaceuticals, and Zydus Pharmaceuticals, among others.

 

 

Market Scope

Market Research Future (MRFR) reveals that the stem cell manufacturing market would be worth USD 17,469.6 Million by 2027-end. Meanwhile, it could achieve a decent growth rate of 17.5% between 2020 and 2027.

Prominent Boosters and Deterrents

Stem cells help effectively manage diseases while also playing an integral role in specialized research activities including genomic testing and personalized medicine. Considering the surging awareness with regard to stem cells’ therapeutic potency and the low availability of effective therapeutic treatment lines for orphan disorders, several private and public stakeholders are investing considerably in the development of advanced stem cell-based technologies.

Emerging nations including South Korea, China, and India, lend strong supportive to their respective stem cell companies through regulatory policies that facilitate the commercialization as well as research activities pertaining to stem cell therapy. These favorable regulatory frameworks in emerging countries are touted to offer lucrative opportunities to the local and global companies in the next several years.

Market Segmentation

Stem cell manufacturing industry can be considered for application, product, and end-users.

The major applications of stem cell manufacturing include research and cell, tissue banking and therapy.

The products mentioned in the MRFR study for stem cell manufacturing market are stem cell lines, consumables, culture media and instruments. The highest share will be captured by the stem cell line segment, which would record a substantial growth rate and also touch USD 9,366.9 Million by 2027-end. Stem cell lines are in high demand due to their potential to replace, repair and regenerate tissues.

The top industry end-users are hospitals & stem cell banks along with pharmaceutical/biotechnology companies & CRO.

Regional Status

The regions where the stem cell manufacturing market will witness growth include Europe, the Americas, the Middle East & Africa/MEA as well as Asia Pacific or APAC.

In 2017, the largest market for stem cell manufacturing belonged to America, which accounted for a share of 49.1% and can continue to thrive significantly in the years to come. Accelerated cases of cancer, strong presence of a well-organized and burgeoning biotechnology and pharmaceutical sectors along with the technical innovations are some of the prime growth boosters. Frequent grants and funding provided by the governments the region enhances the market size as well. In the region, North America is the highest gainer, with the United States standing at the vanguard.

The European market comes second globally and can clock in an attractive CAGR of 17.5% from 2020 to 2027, thanks to the exhaustive stem cell research activities frequently conducted in the region. The large-scale public-private funding as well as grants that facilitate clinical assessment of stem cells for multiple applications also benefit the European market.

Asia Pacific is making significant progress, while China will cover considerable grounds in the global market owing to the developing healthcare infrastructure coupled with the rising disposable income. The market size in the region is further bolstered by the rise in government initiatives aimed at improving the health care industry and facilitating extensive researches on stem cell therapy in view of the growing number of cancer cases.

Leading Companies

STEMCELL Technologies Inc.(US), Bio-Rad Laboratories, Inc(US), Thermo Fisher Scientific(US), Bristol-Myers Squibb Company(US), Lonza (Switzerland), Merck KGaA (Germany), HiMedia Laboratories(India), Athersys, Inc(US), Becton, Dickinson and Company(US), Fujifilm (New York), are the leading companies in the global industry.

 

 

 

Market Research Future (MRFR) announces the publication of its research report –Global Healthcare Regulatory Affairs Outsourcing Market, 2018-2023. The global healthcare regulatory affairs outsourcing market held a market value of USD 3,120.4 million in 2017 and is projected to grow at a CAGR of 9.4% over the forecast period. The healthcare regulatory affairs outsourcing offers medical writing and publishing which plays an important role to develop high-quality documents for the clinical research process. The rising, increasing number of patent expirations and growing research and development activities are some factors that are likely to propel the market growth during the assessment period.

Currently, the global healthcare regulatory affairs outsourcing market is dominated by numerous prominent players. The key players operating in this market offer comprehensive knowledge in managing healthcare regulatory affairs. These companies mainly intend to help firms overcome challenges and accelerate clinical processes.

On a regional basis, the global healthcare regulatory affairs outsourcing market in the Americas is segmented into two major regions, i.e., North America and Latin America. The North American region is likely to hold the major share in the region is due to the increasing prevalence of chronic diseases. The rising prevalence of cancer and other chronic diseases demands the discovery of newer and effective drugs which is anticipated to fuel the market growth in this region. For instance, according to the Centers for Disease Control and Prevention, in 2014, 9,421 new cases of tuberculosis were registered in the US. Moreover, according to the National Cancer Institute, in 2016, around 1,685,210 new cases of cancer had been diagnosed in the US.

The global healthcare regulatory affairs outsourcing market has been segmented into service and end user.

Some Of The Prominent Players In The Global Healthcare Regulatory Affairs Outsourcing Market Are Accell Clinical Research, LLC, Charles River Laboratories International, Inc., Clinilabs, Inc., Criterium Inc., ICON plc, Covance, Inc., Medpace, Inc., PAREXEL International Corporation, Pharmaceutical Product Development, (PPD) LLC, Promedica International, Quintiles Transnational Corporation, WuXi App Tec, and others.

Segment Analysis

The global Healthcare Regulatory Affairs Outsourcing Market is segmented into application, product and end user. On the basis of application, the market is segmented into therapy, research and cell, and tissue banking. The global Healthcare Regulatory Affairs Outsourcing Market by product is segmented into stem cell lines, instruments, consumables and culture media. The stem cell lines segment is expected to lead the market and register a substantial CAGR to reach USD 9,366.9 million by the end of 2023. Due to its unique capabilities for tissue repair, replacement, and regeneration is expected to drive the market growth. On the basis of end user, the market is segmented into pharmaceutical/biotechnology companies & CRO and hospitals & stem cell banks.

Regional Analysis

Geographically, the global Healthcare Regulatory Affairs Outsourcing Market has been segmented into North America, Europe, Asia-Pacific, and the Middle East & Africa. As per MRFR analysis, the Americas was the largest market for Carotid Artery Disease Market in 2017 and is expected to remain dominant during the review period. Europe accounted for a significant market share and is projected to be the second-largest market during the forecast period. Major factors influencing the growth of the market include the presence of major manufacturers, growing prevalence of cancer, growing healthcare expenditure, and increase in technologically-advanced products in Europe are driving the growth of the Healthcare Regulatory Affairs Outsourcing Market in the region. The Asia-Pacific Healthcare Regulatory Affairs Outsourcing Market is one of the fastest growing regions across the globe. Growing population and rising incidence of cancer are likely to drive the growth of the Asia-Pacific market.

Key Findings of the Study:

  • The global Healthcare Regulatory Affairs Outsourcing Marketis projected to reach over USD 17,469.6 million by 2023 at 17.5% CAGR during the review period of 2018 to 2023.
  • Americas accounted for the largest market share with North America being the major contributor to the growth of the market.
  • By product, the stem cell line segment is projected to register the highest CAGR of 7.9% during the forecast period due to the unique capabilities for tissue repair, replacement, and regeneration.
  • Key manufacturers are adopting geographic expansions, corporate acquisitions, and product launches as growth strategies. Moreover, they are focusing on e-commerce for distribution.

 

Market Research Future (MRFR) announces the publication of its research report –Global Healthcare Regulatory Affairs Outsourcing Market, 2018-2023. The global healthcare regulatory affairs outsourcing market held a market value of USD 3,120.4 million in 2017 and is projected to grow at a CAGR of 9.4% over the forecast period. The healthcare regulatory affairs outsourcing offers medical writing and publishing which plays an important role to develop high-quality documents for the clinical research process. The rising, increasing number of patent expirations and growing research and development activities are some factors that are likely to propel the market growth during the assessment period.

Currently, the global healthcare regulatory affairs outsourcing market is dominated by numerous prominent players. The key players operating in this market offer comprehensive knowledge in managing healthcare regulatory affairs. These companies mainly intend to help firms overcome challenges and accelerate clinical processes.

On a regional basis, the global healthcare regulatory affairs outsourcing market in the Americas is segmented into two major regions, i.e., North America and Latin America. The North American region is likely to hold the major share in the region is due to the increasing prevalence of chronic diseases. The rising prevalence of cancer and other chronic diseases demands the discovery of newer and effective drugs which is anticipated to fuel the market growth in this region. For instance, according to the Centers for Disease Control and Prevention, in 2014, 9,421 new cases of tuberculosis were registered in the US. Moreover, according to the National Cancer Institute, in 2016, around 1,685,210 new cases of cancer had been diagnosed in the US.

The global healthcare regulatory affairs outsourcing market has been segmented into service and end user.

Some Of The Prominent Players In The Global Healthcare Regulatory Affairs Outsourcing Market Are Accell Clinical Research, LLC, Charles River Laboratories International, Inc., Clinilabs, Inc., Criterium Inc., ICON plc, Covance, Inc., Medpace, Inc., PAREXEL International Corporation, Pharmaceutical Product Development, (PPD) LLC, Promedica International, Quintiles Transnational Corporation, WuXi App Tec, and others.

Segment Analysis

The global Healthcare Regulatory Affairs Outsourcing Market is segmented into application, product and end user. On the basis of application, the market is segmented into therapy, research and cell, and tissue banking. The global Healthcare Regulatory Affairs Outsourcing Market by product is segmented into stem cell lines, instruments, consumables and culture media. The stem cell lines segment is expected to lead the market and register a substantial CAGR to reach USD 9,366.9 million by the end of 2023. Due to its unique capabilities for tissue repair, replacement, and regeneration is expected to drive the market growth. On the basis of end user, the market is segmented into pharmaceutical/biotechnology companies & CRO and hospitals & stem cell banks.

Regional Analysis

Geographically, the global Healthcare Regulatory Affairs Outsourcing Market has been segmented into North America, Europe, Asia-Pacific, and the Middle East & Africa. As per MRFR analysis, the Americas was the largest market for Carotid Artery Disease Market in 2017 and is expected to remain dominant during the review period. Europe accounted for a significant market share and is projected to be the second-largest market during the forecast period. Major factors influencing the growth of the market include the presence of major manufacturers, growing prevalence of cancer, growing healthcare expenditure, and increase in technologically-advanced products in Europe are driving the growth of the Healthcare Regulatory Affairs Outsourcing Market in the region. The Asia-Pacific Healthcare Regulatory Affairs Outsourcing Market is one of the fastest growing regions across the globe. Growing population and rising incidence of cancer are likely to drive the growth of the Asia-Pacific market.

Key Findings of the Study:

  • The global Healthcare Regulatory Affairs Outsourcing Marketis projected to reach over USD 17,469.6 million by 2023 at 17.5% CAGR during the review period of 2018 to 2023.
  • Americas accounted for the largest market share with North America being the major contributor to the growth of the market.
  • By product, the stem cell line segment is projected to register the highest CAGR of 7.9% during the forecast period due to the unique capabilities for tissue repair, replacement, and regeneration.
  • Key manufacturers are adopting geographic expansions, corporate acquisitions, and product launches as growth strategies. Moreover, they are focusing on e-commerce for distribution.

 

The global eye allergy treatment market is expected to exhibit a strong 5.3% CAGR over the forecast period from 2018 to 2023, according to the latest research report from Market Research Future (MRFR). The report presents a detailed analysis of the global eye allergy treatment market, profiling the leading drivers and restraints operating on the market. The major economic factors operating in the market’s environment are also studied in the report to understand the market’s economic position and standing. The major players operating in the global eye allergy treatment market are also profiled in the report to provide readers with a clear picture of the market’s competitive landscape.

The global eye allergy treatment market is mainly driven by the growing awareness about eye disorders and the growing demand from consumers for effective eye allergy medications. The eyes are among the most delicate organs in the human body and can be grossly affected by several factors, including imbalances in the body as well as extreme changes in the environment. This has driven significant research and development activity in the global eye allergy treatment market in recent years, as ophthalmology has advanced significantly as a major area of medicine. The growing geriatric population is also likely to be a key driver for the global eye allergy treatment market over the forecast period. The eyes grow weak with age, leading to a higher prevalence of ophthalmological conditions among the geriatric than among younger demographics.

Growing air pollution is also likely to be a major driver for the global eye allergy treatment market over the forecast period. Air pollution is a major causative agent for eye allergies, as dust, pollen and other particles are borne on air pollution and can easily reach the eyes. Growing urbanization around the world has driven the extent of air pollution, leading to a growing prevalence of eye allergies. This is likely to drive the demand from the eye allergy treatment market over the forecast period.

Competitive Analysis:

Leading players in the global eye allergy treatment market include Nutra Essential OTC, Shire, Akorn Inc., Nicox, Teva Pharmaceutical Industries Ltd., Santen Pharmaceutical Co. Ltd., Bausch Health, Novartis AG, Johnson & Johnson Services Inc., and Allergan plc. Research into developing more effective formulations for eye allergy treatment is likely to remain a popular avenue among players in the global eye allergy treatment market over the forecast period. Developing formulations with safer ingredients that don’t affect the eyes adversely is also likely to be a priority for players in the eye allergy treatment market.

Segmentation:

The global eye allergy treatment market is segmented on the basis of type, treatment, end use, and region.

By type, the global eye allergy treatment market is segmented into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergy conjunctivitis, and giant papillary conjunctivitis.

By treatment, the global eye allergy treatment market is segmented into medications and allergy shots (immunotherapy). The medications segment is further segmented into artificial tears, decongestants, antihistamines/mast cell stabilizers, oral antihistamines, and corticosteroids. The allergy shots segment is further sub-segmented into subcutaneous immunotherapy treatment and sublingual immunotherapy treatment.

By end use, the global eye allergy treatment market is segmented into hospitals and clinics, and specialty centers.

Regional Analysis:

The Americas hold the largest share of more than 40% in the global eye allergy treatment market and is likely to remain the leading regional market over the forecast period. The Americas market for eye allergy treatment is mainly driven by the growing prevalence of ophthalmological conditions in North America, the growing awareness about ophthalmological conditions, and the growing geriatric population in the region. According to the National Eye Institute, about 3 million cases of conjunctivitis were reported in the U.S. in 2015.

Influenza as an illness can cause severe complications and mess up anybody's medical history. Influenza is of various types and with a variety of deadly symptoms. Hence, early diagnosis of influenza can reduce the chances of further complications. Therefore, with World Health Organization (WHO) confirming about 600 million Influenza cases worldwide, the services offering accurate Influenza diagnosis are going to be in-demand always and become a part of a huge market in the medical sector.

Market Research Future (MRFR) has published a report about the global influenza diagnostics market. This report expects 5.8% CAGR during the forecast period between 2017 and 2023. In terms of cash, this market is expected to grow with US $ 700.7 mn by 2023.

This report analyzes the market, potential for growth during the forecast period, market sizes around the world, key players in the market, product launches and latest research and development (R&D). The global influenza diagnostics market is on the basis of types, tests, and region. The segmentation of types comprises of type A flu, type B flu, type C flu. The three forms of type A are bird flu, seasonal flu, and Swine flu. On the basis of direct fluorescent antibody (DFA) tests, molecular tests, nucleic acid sequence-based amplification (NASBA) tests, rapid influenza detection tests (RIDT), serological assays, simple amplification-based assays (SAMBA) and loop-mediated isothermal amplification-based assays (LAMP). Serological assays are segmented into primary serological tests, secondary serological tests, and tertiary serological tests. Primary serological tests cover enzyme-linked immunosorbent assay (ELISA), immunofluorescent antibody technique (IFAT) and radioimmunoassay (RIA). Secondary Serological tests include agglutination tests, complement fixation tests (CFT), precipitation tests, serum neutralization tests (SNT) and toxin-antitoxin test.

The regional segmentation of the global influenza diagnostics market is into the Americas (North America & South America), Europe, Asia Pacific, and Middle East & Africa (MEA). North America is believed to be the largest market for global influenza diagnostics due to advanced healthcare facilities and the increasing presence of major market players in this region. Compared to North America, South America is a moderately smaller market, but that is not due to lack of demand but due to the lack of awareness, lack of advanced technology and lesser budgets for healthcare. In North America, the largest markets are Canada and the United States of America (USA). After North America, Europe is the largest market for influenza diagnostics.

Key Players

The key players in global influenza diagnostics market include Alere (USA), BD (USA), Becton Dickinson (USA), BioMérieux SA (France), Cepheid (USA), Hardy Diagnostics(USA), LifeSign LLC.(USA), Meridian Bioscience, Inc.(USA), Quidel Corporation (USA), Roche Molecular Systems Inc.(Switzerland), and Sekisui Diagnostics (USA).

Latest Industry News

·         Medical technology company Becton Dickinson (BD), currently a key player in global influenza diagnostics market, has formally opened a new research facility at Plassey Technological Park in Limerick. This business expansion has created 85 new jobs at its Irish operations. Currently, BD employs more than 1,300 employees in Ireland across Drogheda, Dun Laoghaire and its two sites in Limerick.

·         US-based leading molecular diagnostics company, Cepheid Inc, a key player in global influenza diagnostics market, has unveiled its newest configuration in the GeneXpert family of systems, the GeneXpert Edge. An owned subsidiary of Danaher, Cepheid Inc, also announced its ‘Make in India’ initiative regarding which they have plans to establish their manufacturing footprint in the country for Xpert MTB/RIF test cartridges which run on the GeneXpert System.  In the last two years, more than 1,200 Cepheid’s GeneXpert Systems have been installed at various revised national tuberculosis control program (RNTCP) sites in India. Last year, more than 2.5 million cartridges were supplied at various centers of Central TB Division (CTD). The India launch of GeneXpert Edge is expected later this year.[a1] 

 

 [a1]Month and Year of Prs missing

Market Scope

Market Research Future (MRFR) expects the medical billing outsourcing market to chart a relentless growth trajectory in the years ahead. It is projected that after touching USD 6982 million in the year 2017, the market size shall continue to soar rapidly at a rate of CAGR of 12.5% over the analysis period (which is between 2020 and 2027).

Major Growth Boosters and Challenges

Medical billing software and solutions help healthcare billers as well as coders offer efficient administrative services to customers and file claims that provide a host of benefits including reduced errors, accurate bills, lower insurance settlement rates, faster payment, digitalization, and invoice monitoring. Surge in technical innovations along with rise in M&A activities present lucrative opportunities to the medical billing software market.

The medical billing outsourcing industry is growing backed by the growing needs of health insurance firms, in terms of medical office management. The heightened preference for cloud-based medical billing software in clinics and hospitals is the latest trend witnessed in the global market.  The market is inundated with numerous players that are involved in fierce competition. Global firms are working on expanding their presence in emerging countries, which will be a huge challenge for local companies, as the competition will rise in terms of features like quality, pricing, and product differentiation. The global market witnesses established vendors indulging in competitive strategies such as collaboration, acquisition, expansion, product launch and partnership, to improve their standing.

Market Segmentation

The global market for medical billing outsourcing has been divided with respect to component, service, and end user.

The components considered in the MRFR study of the medical billing outsourcing market include in house as well as outsourced.

The services anlayzed in the MRFR report are middle, back end and front end.

Top end users mentioned in the market study are physician’s office, hospitals, and others. 

Regional Study

The Americas and APAC or Asia Pacific as well as MEA or Middle East and Africa and Europe are the key regions where the medical billing outsourcing market will witness growth in the years ahead.

The American market has secured the lead and is expected to maintain its winning streak throughout the projected timeline, thanks to the incredible expansion of the information technology sector. Surging use of medical billing outsourcing software and solutions by a rising number of hospitals also adds to the market value. High industrialization rate and a well-established healthcare industry present in the region add to the market value. Canada and the US are the highest gainers in the region, considering the mounting need to bring down the skyrocketing medical bills as well as the significant per capita health care expenditure. Surge in R&D spending and the resultant increase in the introduction of new technologies also enhance the market share in the region.

Europe remains the second highest gainer in the global medical billing outsourcing industry, since the region expends considerably on exhaustive research and development activities. The healthcare sector in the region emphasizes majorly on transparent billing methods and is largely supported by the government to carry out research and development processes, which could translate into substantial market growth in subsequent years.

Asia Pacific seems to be progressing at the fastest pace, backed by the surging burden of communicable diseases and the expanding patient pol. India and China are some of the fastest growing markets in the region, in view of the strong support of the government that encourage the set-up of new and modern medical facilities to cater to the growing needs of the burgeoning population. Rising cases of chronic diseases and escalation in internet use among healthcare workers and patients can also benefit the APAC market in the following years.

Reputed Vendors

R1 RCM Inc., Allscripts, Cerner Corporation, EClinical Works, Experian Information Solutions Inc., GENERAL ELECTRIC COMPANY, Genpact, HCL Technologies Limited, Kareo, Inc., McKesson Corporation, Quest Diagnostics Incorporated and The SSI Groups Inc are some of the leading market contenders profiled in the MRFR report. 

Overview

The surgical scalpel is a sharp bladed tool for performing surgeries and anatomical dissections. With the increase in population and chronic diseases, the global market for surgical scalpel is at a higher growth rate than before. Surgical scalpel market is estimated to see a growth graph reaching near 04% annually until the projected time. Increase in private sector healthcare facilities has also added some pace to the growth rate. For such products, referred to as low-risk devices, there are fewer regulations which help in faster market growth with the minimum number of risks.

The surgical scalpel market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 565 million in 2017 and is projected to register a CAGR of 3.7% over the forecast period.

There are errors made at handling levels, which lead to severe injuries and health issues. Injuries and mistakes among patients and health workers like mismanagement of tools, wounds, hospital errors and similar factors are responsible for the limited growth of the global market. Also, injuries by surgical scalpel possess a higher risk of transmission of diseases through the blood. Another factor responsible for holding back the global scalpel market is less professionalism; reports have indicated that some medical facilities are unable to handle such devices in the form of usage and proper disposal.

Scalpels consist of the blade and handle. Blades are generally disposed of after a single use and handles are used after sterilization. Size and shape of surgical scalpel vary with the type of operation to be performed. Investors and manufacturers based on market research reports are now looking for new areas with cheap sources and high usability. Through proper channels of market surveys, such areas can be identified.

Regional Overview

In current projection, there are four major regions America, Europe, Asia Pacific and the Middle East & Africa.

With the advancements and rapidly increasing demand for better health procedures, America is the current leader in consumption due to an increase in various chronic diseases and manufacturing with the presence of global leaders. Europe is in second place with rising demand for surgical procedures and advanced manufacturing facilities. The Asia Pacific is also growing at a decent rate at present. It will come out as the fastest growing global market for surgical scalpels industry because it has cheaper labour, vast population and increasing demand for new & better medical healthcare facilities. The same market will show a slower growth rate in the rest of the regions.

Recent Industry News

Industry majors are now looking for new options and scopes on global levels. Investors and manufacturers are currently in search of remoter places with low production costs and high usability. Keeping this factor in mind, they are now getting interested in Asia Pacific market as there is the presence of large masses, high development rate and cheap labour is available which can help them to reach new levels of success.

 

Market Analysis

The veterinary dental equipment market is likely to grow at a 9.5% CAGR between 2018- 2023, reveals the new Market Research Future (MRFR) report. Veterinary dentistry equipment, simply put, are sterile, powered, or handheld tools that veterinary dentists use to perform various procedures on animals such as extraction of tooth, repair tumors of oral hard and soft tissues, and remove plaques or tooth calculus among others. 


Numerous factors are adding to the veterinary dentistry instruments & equipment market demand. Such factors, as revealed by the latest MRFR report, include increasing incidence of periodontal disease in animals, rising expenditure on pet insurance, untapped emerging markets, technological advances, and growing awareness about animal healthcare. Additional factors propelling the veterinary dental equipment market growth include the availability of attractive reimbursement plans, increasing incidence of oral diseases in companion pets, and an increasing number of veterinary practitioners. 


Market Segmentation 

The Market Research Future Report provides an inclusive segmental analysis of the veterinary dental equipment market based on end user, animal type, and product. 


By animal type, the global veterinary dental equipment market is segmented into companion animals, large animals, and others. Of these, companion animals will dominate the market over the forecast period. 


By end user, the veterinary dental equipment market is segmented into research and academic institutes, veterinary clinics, veterinary hospitals, and others. Of these, the veterinary hospital will have a major share in the market over the forecast period. 


Regional Analysis 

By region, the global veterinary dental equipment market report covers the growth opportunities and recent trends across Europe, the Americas, the Asia Pacific (APAC), and the Middle East and Africa (MEA). Of these, the Americas will command the largest share in the market over the forecast period for the presence of top market players in the region and rising expenditure on pet insurance.


The global veterinary dental equipment market in Europe is predicted to hold the second-largest share over the forecast period chiefly for the rising incidence of periodontal diseases. 


The global veterinary dental equipment market in the APAC region is predicted to grow at a high CAGR over the forecast period for the rising awareness regarding animal healthcare. 


The global veterinary dental equipment market in the MEA is predicted to have a small share over the forecast period for low economic development, particularly in the African region. 


Key Players

Notable players profiled in the global veterinary dental equipment market report include Technik Veterinary, Midmark Corporation, MAI Animal Health, J & J Instruments, Integra Lifesciences, iM3 Pty Ltd, Henry Schein, Eickemeyer, Dispomed, Dentalaire, Cislak Manufacturing, Charles Brungart, Inc. (Cbi), and Acteon Group. Industry players have used strategies such as strategic alliances, mergers, partnerships, acquisitions, new product launches, among others, to create a niche in the market. 

Pages: 1 2 3 4 5 ... » »»